TY - JOUR
T1 - Cutaneous involvement with marginal zone lymphoma
AU - Gerami, Pedram
AU - Wickless, Scott C.
AU - Querfeld, Christiane
AU - Rosen, Steven T.
AU - Kuzel, Timothy M.
AU - Guitart, Joan
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2010/7
Y1 - 2010/7
N2 - Background: Cutaneous marginal zone lymphoma (MZL) may be a primary cutaneous condition or the result of secondary involvement from noncutaneous MZL. Distinguishing primary cutaneous MZL (PCMZL) from secondary cutaneous MZL (SCMZL) is of utmost importance for prognostic and therapeutic approach. Objective: We describe the clinical and histologic features of 4 cases of SCMZL (3 cases of nodal MZL and one case of orbital extranodal MZL), compare them with a cohort of 30 cases of PCMZL, and describe distinctive features of SCMZL. Methods: Thirty cases of PCMZL and 4 cases of non-PCMZL with secondary skin involvement were identified in our cutaneous lymphoma and dermatopathology databases. The medical records were reviewed regarding clinical, histologic, laboratory, and radiologic findings; disease course; response to treatment; and follow-up. All cases were reviewed by 3 dermatopathologists. Results: The histopathological and immunohistochemical features of SCMZL were indistinguishable from our cases with PCMZL. However, the clinical presentation in SCMZL appeared to be distinct. We observed these lesions in an older patient population and in 3 of 4 cases the lesions predominantly involved the head/neck area. Limitations: As PCMZL and SCMZLs are exceedingly rare, only 34 patients were identified in this single-institution study. Conclusions: The histologic and immunophenotypic changes in skin lesions from SCMZL may be indistinguishable from those in PCMZL. However, there may be some differences in the typical clinical presentation. PCMZL may be seen in younger patients and favors the trunk and extremities whereas MZL secondarily involving the skin favors the head/neck regions and is limited to older patients. Because there may be considerable overlap in the clinical presentations for patients with primary and secondary cutaneous disease, it is not unreasonable to perform a systemic evaluation for all patients.
AB - Background: Cutaneous marginal zone lymphoma (MZL) may be a primary cutaneous condition or the result of secondary involvement from noncutaneous MZL. Distinguishing primary cutaneous MZL (PCMZL) from secondary cutaneous MZL (SCMZL) is of utmost importance for prognostic and therapeutic approach. Objective: We describe the clinical and histologic features of 4 cases of SCMZL (3 cases of nodal MZL and one case of orbital extranodal MZL), compare them with a cohort of 30 cases of PCMZL, and describe distinctive features of SCMZL. Methods: Thirty cases of PCMZL and 4 cases of non-PCMZL with secondary skin involvement were identified in our cutaneous lymphoma and dermatopathology databases. The medical records were reviewed regarding clinical, histologic, laboratory, and radiologic findings; disease course; response to treatment; and follow-up. All cases were reviewed by 3 dermatopathologists. Results: The histopathological and immunohistochemical features of SCMZL were indistinguishable from our cases with PCMZL. However, the clinical presentation in SCMZL appeared to be distinct. We observed these lesions in an older patient population and in 3 of 4 cases the lesions predominantly involved the head/neck area. Limitations: As PCMZL and SCMZLs are exceedingly rare, only 34 patients were identified in this single-institution study. Conclusions: The histologic and immunophenotypic changes in skin lesions from SCMZL may be indistinguishable from those in PCMZL. However, there may be some differences in the typical clinical presentation. PCMZL may be seen in younger patients and favors the trunk and extremities whereas MZL secondarily involving the skin favors the head/neck regions and is limited to older patients. Because there may be considerable overlap in the clinical presentations for patients with primary and secondary cutaneous disease, it is not unreasonable to perform a systemic evaluation for all patients.
KW - lymphoma
KW - marginal zone lymphoma
KW - mucosa-associated lymphoid tissue
UR - http://www.scopus.com/inward/record.url?scp=77953292076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953292076&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2009.07.047
DO - 10.1016/j.jaad.2009.07.047
M3 - Review article
C2 - 20462658
AN - SCOPUS:77953292076
SN - 0190-9622
VL - 63
SP - 142
EP - 145
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 1
ER -